Clozapine Across Treatment-Resistant Symptom Dimensions: A Conceptual Review and Transdiagnostic Rationale for Child and Adolescent Psychiatry

Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia, yet in children and adolescents it remains off-label and underused, constrained by safety concerns and scarce pediatric-specific evidence. Its benefits may extend beyond any single diagnostic category to severe, treatment-resistant dimensions of psychopathology that recur across diagnoses. This review traces clozapine’s history in youth, synthesizes the current evidence, and organizes it by domains of treatment resistance: psychosis, aggression, affective symptoms, suicidality and self-directed harm, and catatonia, with sections on real-world outcomes, clinical management, and safety. Randomized controlled data are confined to treatment-resistant early-onset schizophrenia and to one small trial in conduct disorder, with the first prospective open-label trial now available in autistic youth. Elsewhere the evidence is observational and of lower certainty, although convergent for aggression, suicidality, mood, and catatonia. The strongest transdiagnostic evidence is register-based and within-individual, drawn from cohorts aged 16 years and older, and spans psychotic and affective disorders; the pediatric gap concerns study design as well as sample size. Because pharmacovigilance data show that mortality is not concentrated in the hematological domain, safe use requires surveillance beyond blood counts, therapeutic drug monitoring, and safeguards over drug supply when suicide risk is present. Viewing clozapine as a treatment option defined by symptom severity and refractoriness may support rational use in severely ill youth, but the proposal remains preliminary: a conceptual framework that requires prospective, dimensionally designed pediatric studies. Clozapine’s potential transdiagnostic anti-suicidal effect merits priority investigation, given that suicide is a leading cause of death in adolescence.

Authors

Institutions

Publication Details

Journal
Future Pharmacology
Published
2026-10-14
DOI
https://doi.org/10.3390/futurepharmacol6040057
Primary Topic
Schizophrenia research and treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clozapine Across Treatment-Resistant Symptom Dimensions: A Conceptual Review and Transdiagnostic Rationale for Child and Adolescent Psychiatry

Ana Soledade Graeff‐Martins, Lamark de Oliveira, André Luiz Schuh Teixeira, Olívia Sorato Bezerra et al.
Future Pharmacology
Schizophrenia research and treatment
article

Clozapine Across Treatment-Resistant Symptom Dimensions: A Conceptual Review and Transdiagnostic Rationale for Child and Adolescent Psychiatry

Ana Soledade Graeff‐Martins, Lamark de Oliveira, André Luiz Schuh Teixeira, Olívia Sorato Bezerra, Felipe de Moura Manjabosco, Gabriela Bezerra Sorato
article en

Abstract

Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia, yet in children and adolescents it remains off-label and underused, constrained by safety concerns and scarce pediatric-specific evidence. Its benefits may extend beyond any single diagnostic category to severe, treatment-resistant dimensions of psychopathology that recur across diagnoses. This review traces clozapine’s history in youth, synthesizes the current evidence, and organizes it by domains of treatment resistance: psychosis, aggression, affective symptoms, suicidality and self-directed harm, and catatonia, with sections on real-world outcomes, clinical management, and safety. Randomized controlled data are confined to treatment-resistant early-onset schizophrenia and to one small trial in conduct disorder, with the first prospective open-label trial now available in autistic youth. Elsewhere the evidence is observational and of lower certainty, although convergent for aggression, suicidality, mood, and catatonia. The strongest transdiagnostic evidence is register-based and within-individual, drawn from cohorts aged 16 years and older, and spans psychotic and affective disorders; the pediatric gap concerns study design as well as sample size. Because pharmacovigilance data show that mortality is not concentrated in the hematological domain, safe use requires surveillance beyond blood counts, therapeutic drug monitoring, and safeguards over drug supply when suicide risk is present. Viewing clozapine as a treatment option defined by symptom severity and refractoriness may support rational use in severely ill youth, but the proposal remains preliminary: a conceptual framework that requires prospective, dimensionally designed pediatric studies. Clozapine’s potential transdiagnostic anti-suicidal effect merits priority investigation, given that suicide is a leading cause of death in adolescence.

Future PharmacologyVol. 6(4)
Universidade Federal do Rio Grande do Sul (BR), Universidade Federal de Ciências da Saúde de Porto Alegre (BR), Hospital de Clínicas de Porto Alegre (BR)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Good health and well-being
Openalex Percentile: Top 13%
Schizophrenia research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.